Showing 3471-3480 of 5063 results for "".
Cosmetic Bootcamp 2019: Presenter Recaps
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/cosmetic-bootcamp-2019-presenter-recaps/19631/In its 15th year, Cosmetic Bootcamp continues to bring together core aesthetic physicians to earn about new and emerging interventions. Mary Lupo, MD; Jeanine Downie, MD; Jose Raul Montes, MD; Diane Berson, MD; Ava Shamban, MD; and Deborah Sherman, MD recap their presentations.Thread Lifting 4.0
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/thread-lifting-40/19603/Today’s thread lifts bring more to the table than previous iterations. Older threads lifted sagging facial tissue, but now they are absorbable and biostimulatory, which means they can lift and add volume to the face and also aid in scar remodelling, explains Hooman Khorasani, MD.FDA Approvals, Acne Insights, EPI Gets Cloderm
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-fda-approvals-acne-insights-epi-gets-cloderm/18230/In a flurry of approvals, FDA gives the nod to Almirall's Seysara (sarecycline), Ortho Dermatologics' Bryhali (halobetasol propionate, 0.01%) Lotion, Paratek Pharmaceuticals' Nuzyra (omadacycline), and Regeneron's Libtayo (cemiplimab). Research shows top earners across various fields in the US mayItch Be Gone
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/itch-be-gone/18524/Could botulinum toxins be the answer for non-histaminergic itch? Erin Gilbert, MD discusses her research in this area and results she's seen to date.Elections and Markets, Encore and Biofrontera Launches, More
https://practicaldermatology.com/topics/practice-management/dermwiretv-elections-and-markets-encore-and-biofrontera-launches-more/18564/Election years bring market uncertainty, but should you be making any changes to your portfolio now? Financial experts weigh in on why—no matter the results—there's no need for panic. Allergan launches a new campaign, ActuallySheCan, to empower young women. Several new products are now available forGalderma, Allergan Rosacea News, Dupilumab Data
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-galderma-allergan-rosacea-news-dupilumab-data/18591/Galderma Laboratories launched a new pump dispenser design for Mirvaso (brimonidine) Topical Gel, 0.33. The FDA has accepted Allergan's New Drug Application (NDA) filing for oxymetazoline cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema assoSRT100: Innovating Topical Radiation Therapy for Skin Cancers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/srt100-innovating-topical-radiation-therapy-for-skin-cancers/19041/The United States has become one of the chief areas of non-melanoma as well as melanoma skin cancer. One of the first treatments that was invented by dermatologists has been the use of radiation therapy for skin cancer. George Miller McKee, who is the father of many of the treatments of both melanoDermwireTV — Revance’s Neurotoxin Promising, Celebs Fight Melanoma with L’Oreal
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-mdash-revance-rsquo-s-neurotoxin-promising-celebs-fight-melanoma-with-l-rsquo-oreal/19138/In this weeks DermwireTV, patient safety is explored, L'Oreal supports melanoma research and Revance reports positive data for novel neurotoxin.DermWire TV: Kysse Approved, Sunscreen Use Trends, AbbVie/Allergan Deal
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwire-tv-kysse-approved-sunscreen-use-trends-abbvieallergan-deal/19812/Galderma's Restylane Kysse is now FDA approved for lip augmentation and the correction of wrinkles around the upper lips in adults. Americans understand that sunscreen use is important to protect the skin, but they still don’t use SPF regularly, AAD data reveal. AbbVie has completed its acquisitionExpanding the Role of Topicals in Atopic Dermatitis
https://practicaldermatology.com/programs/practical-dermatology-updates-in-atopic-dermatitis/expanding-the-role-of-topicals-in-atopic-dermatitis/57282/Tina Bhutani-Jacques, MD, MAS, discusses how newer nonsteroidal topical therapies are changing the treatment paradigm in atopic dermatitis, expanding options for patients across disease severities and supporting long-term disease management.